Compare LEE & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | ASMB |
|---|---|---|
| Founded | 1890 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 442.9M |
| IPO Year | 2025 | 2010 |
| Metric | LEE | ASMB |
|---|---|---|
| Price | $10.50 | $22.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | 69.8K | ★ 162.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $543,955,000.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $15.54 |
| 52 Week High | $11.88 | $39.71 |
| Indicator | LEE | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 28.84 |
| Support Level | $7.95 | $20.23 |
| Resistance Level | $11.88 | $31.21 |
| Average True Range (ATR) | 0.90 | 1.68 |
| MACD | 0.10 | -0.57 |
| Stochastic Oscillator | 55.30 | 0.98 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.